Glenmark Life Sciences Limited (GLS.NS)
- Previous Close
750.50 - Open
759.95 - Bid --
- Ask --
- Day's Range
755.40 - 825.00 - 52 Week Range
500.10 - 906.00 - Volume
584,260 - Avg. Volume
156,389 - Market Cap (intraday)
100.073B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
19.22 - EPS (TTM)
42.40 - Earnings Date --
- Forward Dividend & Yield 43.50 (5.26%)
- Ex-Dividend Date Oct 17, 2023
- 1y Target Est
899.33
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited.
www.glenmarklifesciences.com1,824
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: GLS.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLS.NS
Valuation Measures
Market Cap
92.16B
Enterprise Value
88.41B
Trailing P/E
19.55
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.03
Price/Book (mrq)
3.94
Enterprise Value/Revenue
3.87
Enterprise Value/EBITDA
12.88
Financial Highlights
Profitability and Income Statement
Profit Margin
21.93%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
23.68B
Net Income Avi to Common (ttm)
5.19B
Diluted EPS (ttm)
42.40
Balance Sheet and Cash Flow
Total Cash (mrq)
4.43B
Total Debt/Equity (mrq)
0.76%
Levered Free Cash Flow (ttm)
--
Research Analysis: GLS.NS
Company Insights: GLS.NS
GLS.NS does not have Company Insights